CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

NCT06430437 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT300

EST. COMPLETION2026-02

Conditions

Non-Small Cell Lung Cancer With HER2- Mutations

Interventions

SHR-A1811PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin

Study details

SPONSORJiangsu HengRui Medicine Co., Ltd.

START DATE2024-07-29

Related company profiles

Hengrui Medicine

600276.SS

Primary source

ClinicalTrials.gov record NCT06430437 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06430437
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record